Biogen (BIIB) Cash & Equivalents (2009 - 2026)

Biogen's Cash & Equivalents history runs 18 years deep, the most recent figure standing at $3.4 billion for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 30.19% year-over-year to $3.4 billion; the TTM figure through Mar 2026 stood at $3.4 billion (up 30.19% YoY), while the FY2025 annual figure was $3.0 billion, up 26.67% from the prior year.
• Cash & Equivalents was $3.4 billion for Q1 2026 at Biogen, up from $3.0 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $3.9 billion in Q3 2025 to a low of $1.0 billion in Q4 2023.
• Historically, Cash & Equivalents has averaged $2.5 billion across 5 years, with a median of $2.6 billion in 2023.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents plunged 69.29% in 2023, then soared 141.84% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $3.4 billion in 2022, then slumped by 69.29% to $1.0 billion in 2023, then jumped by 126.21% to $2.4 billion in 2024, then increased by 26.67% to $3.0 billion in 2025, then increased by 12.44% to $3.4 billion in 2026.
• The last three Cash & Equivalents figures came in at $3.4 billion (Q1 2026), $3.0 billion (Q4 2025), and $3.9 billion (Q3 2025), per Business Quant data.